WO2002083651A3 - Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques - Google Patents

Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques Download PDF

Info

Publication number
WO2002083651A3
WO2002083651A3 PCT/CA2002/000512 CA0200512W WO02083651A3 WO 2002083651 A3 WO2002083651 A3 WO 2002083651A3 CA 0200512 W CA0200512 W CA 0200512W WO 02083651 A3 WO02083651 A3 WO 02083651A3
Authority
WO
WIPO (PCT)
Prior art keywords
ictogenic
compounds
pyrimidine compounds
methods
epileptogenic agents
Prior art date
Application number
PCT/CA2002/000512
Other languages
English (en)
Other versions
WO2002083651A2 (fr
Inventor
Donald F Weaver
Buhendwa Musole Guillain
John R Carran
Kathryn Jones
Original Assignee
Univ Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kingston filed Critical Univ Kingston
Priority to CA002444148A priority Critical patent/CA2444148A1/fr
Priority to JP2002581407A priority patent/JP2004527535A/ja
Priority to EP02717913A priority patent/EP1385831A2/fr
Publication of WO2002083651A2 publication Critical patent/WO2002083651A2/fr
Publication of WO2002083651A3 publication Critical patent/WO2002083651A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des procédés et des composés servant à inhiber des troubles convulsifs, y compris l'épilepsie. Les procédés et les composés selon l'invention inhibent ou préviennent l'ictogénèse et/ou l'épileptogénèse. La présente invention porte également sur des procédés de préparation desdits composés. Dans un mode préféré de réalisation, les composés comprennent la formule :
PCT/CA2002/000512 2001-04-11 2002-04-11 Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques WO2002083651A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002444148A CA2444148A1 (fr) 2001-04-11 2002-04-11 Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques
JP2002581407A JP2004527535A (ja) 2001-04-11 2002-04-11 抗発作発生剤および／または抗癲癇誘発剤としてのピリミジン化合物
EP02717913A EP1385831A2 (fr) 2001-04-11 2002-04-11 Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US28298701P 2001-04-11 2001-04-11
US60/282,987 2001-04-11
US28594001P 2001-04-23 2001-04-23
US60/285,940 2001-04-23
US31074801P 2001-08-07 2001-08-07
US60/310,748 2001-08-07
US9993402A 2002-03-13 2002-03-13
US10/099,934 2002-03-13

Publications (2)

Publication Number Publication Date
WO2002083651A2 WO2002083651A2 (fr) 2002-10-24
WO2002083651A3 true WO2002083651A3 (fr) 2002-12-19

Family

ID=27493095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000512 WO2002083651A2 (fr) 2001-04-11 2002-04-11 Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques

Country Status (4)

Country Link
EP (1) EP1385831A2 (fr)
JP (1) JP2004527535A (fr)
CA (1) CA2444148A1 (fr)
WO (1) WO2002083651A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009559A2 (fr) * 2002-07-18 2004-01-29 Queen's University At Kingston Composes de dihydro-uracile utilises comme agents anti-ictogenes ou anti-epileptogenes
CA2523739A1 (fr) * 2003-04-25 2004-11-11 University College Cardiff Consultants Limited Composes heterocycliques destines a etre utilises dans le traitement d'infections virales
BRPI0508310A (pt) * 2004-03-02 2007-07-24 Hoffmann La Roche derivados de 4-(sulfanil-pirimidin-4-ilmetil)-morfolina e compostos relacionados como ligandos do receptor gaba, para o tratamento de ansiedade, depressão e epilepsia
AU2009209811B2 (en) * 2008-01-30 2011-07-21 Shin Poong Pharmaceutical Co., Ltd. Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
DE102008030091B4 (de) * 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
US9809571B2 (en) 2013-01-07 2017-11-07 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2015103489A1 (fr) * 2014-01-03 2015-07-09 University Of Southern California Hétéroatome contenant des inhibiteurs de la désoxyuridine triphosphatase
CN103788095A (zh) * 2014-01-20 2014-05-14 四川大学华西医院 2,4(1h,3h)-嘧啶二酮衍生物及其制备方法
CN104788389A (zh) * 2015-04-09 2015-07-22 新乡市创新生物科技有限公司 一种5-溴尿嘧啶的制备方法
JP6836589B2 (ja) 2015-07-08 2021-03-03 シーブイ６ セラピューティクス （エヌアイ） リミテッド ヒダントインを含むデオキシウリジントリホスファターゼ阻害剤
WO2017006271A1 (fr) 2015-07-08 2017-01-12 University Of Southern California Inhibiteurs de désoxyuridine triphosphatase contenant une liaison sulfonyle aminée
WO2017006270A1 (fr) 2015-07-08 2017-01-12 University Of Southern California Inhibiteurs de la désoxyuridine triphosphatase
WO2017006283A1 (fr) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Inhibiteurs de désoxyuridine triphosphatase contenant une liaison cyclopropano
WO2017123823A1 (fr) * 2016-01-12 2017-07-20 Bioelectron Technology Corporation Inhibiteurs de sulfure:quinone oxydoréductase alkyle, acyle, urée, et aza-uracile
US11174271B2 (en) 2016-11-23 2021-11-16 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098208A1 (fr) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Inhibiteurs de désoxyuridine triphosphatase liés à un cycle azote
US10858344B2 (en) 2016-11-23 2020-12-08 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11014924B2 (en) 2016-11-23 2021-05-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098209A1 (fr) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Composés aminosulfonyle
WO2018128720A1 (fr) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Composés contenant de l'uracile

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252576A (en) * 1988-07-18 1993-10-12 Yamasa Shoyu Kabushiki Kaisha 1-amino-5-halogenouracils, process for their preparation, and central nervous system depressants containing same as active ingredient
DE4300912A1 (de) * 1993-01-15 1994-07-21 Merck Patent Gmbh Chinazolinderivate
WO1995019346A1 (fr) * 1994-01-14 1995-07-20 Sandoz Ltd. Quinazoline-2,4-diones
WO2000011952A1 (fr) * 1998-08-31 2000-03-09 Pro-Neuron, Inc. Compositions et procedes de traitement des maladies mitochondriales
WO2000050043A1 (fr) * 1999-02-23 2000-08-31 The Regents Of The University Of California Procedes de traitement de troubles mitochondriaux
WO2001051490A1 (fr) * 2000-01-14 2001-07-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Analogues nucleosidiques de methanocarba cycloalkyle

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252576A (en) * 1988-07-18 1993-10-12 Yamasa Shoyu Kabushiki Kaisha 1-amino-5-halogenouracils, process for their preparation, and central nervous system depressants containing same as active ingredient
DE4300912A1 (de) * 1993-01-15 1994-07-21 Merck Patent Gmbh Chinazolinderivate
WO1995019346A1 (fr) * 1994-01-14 1995-07-20 Sandoz Ltd. Quinazoline-2,4-diones
WO2000011952A1 (fr) * 1998-08-31 2000-03-09 Pro-Neuron, Inc. Compositions et procedes de traitement des maladies mitochondriales
WO2000050043A1 (fr) * 1999-02-23 2000-08-31 The Regents Of The University Of California Procedes de traitement de troubles mitochondriaux
WO2001051490A1 (fr) * 2000-01-14 2001-07-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Analogues nucleosidiques de methanocarba cycloalkyle

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CONNOLLY G P ET AL: "Uridine and its nucleotides: biological actions, therapeutic potentials", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 20, no. 5, 1 May 1999 (1999-05-01), pages 218 - 225, XP004170246, ISSN: 0165-6147 *

Also Published As

Publication number Publication date
JP2004527535A (ja) 2004-09-09
CA2444148A1 (fr) 2002-10-24
EP1385831A2 (fr) 2004-02-04
WO2002083651A2 (fr) 2002-10-24

Similar Documents

Publication Publication Date Title
WO2004009559A3 (fr) Composes de dihydro-uracile utilises comme agents anti-ictogenes ou anti-epileptogenes
WO2002083651A3 (fr) Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques
WO1998040055A3 (fr) Agents anti-epileptogenes
AU2002352832A1 (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them
WO2002073208A3 (fr) Agents antiepileptogenes
WO2004028454A3 (fr) 1, 3, 5-triazines destinees au traitement de maladies virales
AP1869A (en) b2- Adrenergic receptor agonists.
WO2001006989A3 (fr) Procedes et compositions permettant d'inhiber l'accumulation des polypeptides associee aux troubles neurologiques
EP1478322A4 (fr) Beta-2'-OU 3'-HALONUCLEOSIDES
WO1999054326A8 (fr) Dihydropyrimidines
WO2003042214A3 (fr) Antagonistes de recepteur d'adenosine a¿2b?
ZA979961B (en) 5-HT1F agonists
NO20022655D0 (no) <Beta>-2-adrenerge reseptoragonister
WO2002064594A3 (fr) Pyrido-pyrimidines substituees en position 6
WO2004084453A3 (fr) Procedes de fabrication de 2'-desoxy-$g(b)-l-nucleosides
EP0835869A3 (fr) Agonistes du Récepteur sérotonine 5-HT1F
WO2003057145A3 (fr) 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones substitues, leurs derives et leurs utilisations
MXPA03009527A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE INDENOS 1,3-SUSTITUIDOS Y COMPUESTOS AZAPOLICICLICOS CONDENSADOS CON ARILO.
WO2001098279A3 (fr) Bis-arylsulfones
WO2002053519A3 (fr) Analogues de polyamine hydrophobe et procedes d'utilisation correspondants
HUP0303590A3 (en) Method for the production of 4,6-diaminopyrimido[5,4-d]pyrimidines
AU2759800A (en) Processes and intermediates for the preparation of 1,3-oxazin-6-ones and uracils
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
WO2000021513A3 (fr) Procedes pour traiter la sclerose en plaques
WO2003051299A3 (fr) Rifamycines au sulfhydryle et utilisations de ces dernieres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2444148

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002581407

Country of ref document: JP

Ref document number: 528880

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002249037

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002717913

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002717913

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642